US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
SI1324776T2
(en)
|
2000-10-12 |
2018-06-29 |
Genentech, Inc. |
Concentrated protein formulations with reduced viscosity
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
US20080026068A1
(en)
*
|
2001-08-16 |
2008-01-31 |
Baxter Healthcare S.A. |
Pulmonary delivery of spherical insulin microparticles
|
KR100913714B1
(ko)
*
|
2001-11-08 |
2009-08-24 |
패시트 바이오테크 코포레이션 |
Igg 항체의 안정한 액상 약학 제형물
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
AU2004229335C1
(en)
|
2003-04-04 |
2010-06-17 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
CA2532966C
(fr)
*
|
2003-07-15 |
2012-12-04 |
Chugai Seiyaku Kabushiki Kaisha |
Production d'igm par des cellules transformees et methodes de quantification de cette production
|
EP1686137A4
(fr)
|
2003-10-09 |
2009-10-28 |
Chugai Pharmaceutical Co Ltd |
Methode de stabilisation de solution proteinique
|
ATE518888T1
(de)
|
2003-10-09 |
2011-08-15 |
Chugai Pharmaceutical Co Ltd |
Stabilisierte lösung mit hoher igm-konzentration
|
US20070184050A1
(en)
*
|
2003-12-25 |
2007-08-09 |
Kirin Beer Kabushiki Kaisha |
Stable water-based medicinal preparation containing antibody
|
CA2555791A1
(fr)
*
|
2004-02-12 |
2005-08-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Formulations liquides fortement concentrees d'anticorps anti-egfr
|
US8728525B2
(en)
*
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
DK1765294T3
(da)
|
2004-05-12 |
2008-11-10 |
Baxter Int |
Nukleinsyremikrokugler samt deres fremstilling og afgivelse
|
EP1753404A1
(fr)
*
|
2004-05-12 |
2007-02-21 |
Baxter International Inc. |
Microsphères contenant des protéines et présentant un potentiel d"injectabilité à d"importants degrés de concentration de l"agent concerné
|
US7884085B2
(en)
*
|
2004-05-12 |
2011-02-08 |
Baxter International Inc. |
Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
|
TW200621282A
(en)
*
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP2008523815A
(ja)
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
認知の改善における使用のためのヒト化アミロイドβ抗体
|
SV2008002394A
(es)
*
|
2005-01-28 |
2008-02-08 |
Wyeth Corp |
Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
US9493569B2
(en)
|
2005-03-31 |
2016-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Structural isomers of sc(Fv)2
|
JP5053264B2
(ja)
|
2005-05-19 |
2012-10-17 |
アムジェン インコーポレイテッド |
抗体の安定性を増加させるための組成物および方法
|
CN101262885B
(zh)
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
含有sc(Fv)2的药物组合物
|
CA2610987C
(fr)
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilisant pour une preparation de proteine contenant de la meglumine et son utilisation
|
KR20080031684A
(ko)
|
2005-06-14 |
2008-04-10 |
암젠 인코포레이티드 |
자가 - 완충성 단백질 제형
|
CN100361709C
(zh)
*
|
2005-08-30 |
2008-01-16 |
山东省生物药物研究院 |
一种对生命活性物质有保护作用的糖类组合
|
AU2006330858A1
(en)
|
2005-12-21 |
2007-07-05 |
Wyeth |
Protein formulations with reduced viscosity and uses thereof
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
AU2007240732B2
(en)
*
|
2006-04-21 |
2013-07-04 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
JP5118139B2
(ja)
*
|
2006-08-04 |
2013-01-16 |
バクスター・インターナショナル・インコーポレイテッド |
新規発症自己免疫性糖尿病を予防および/または逆転させるためのマイクロスフィアに基づく組成物
|
TW200831129A
(en)
*
|
2006-10-06 |
2008-08-01 |
Amgen Inc |
Stable formulations
|
CL2007002881A1
(es)
*
|
2006-10-20 |
2008-05-09 |
Amgen Inc |
Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
|
EP2132312B1
(fr)
|
2007-03-27 |
2016-01-27 |
Sea Lane Biotechnologies,llc. |
Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps
|
CA2681752A1
(fr)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Anticorps anti-1l-12 humains cristallins
|
MX2009011218A
(es)
*
|
2007-04-17 |
2010-02-11 |
Baxter Int |
Microparticulas de acido nucleico para administracion pulmonar.
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
EP2182983B1
(fr)
|
2007-07-27 |
2014-05-21 |
Janssen Alzheimer Immunotherapy |
Traitement de maladies amyloïdogéniques avec anti-abeta anticorps humanise
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
HUE037409T2
(hu)
*
|
2007-10-30 |
2018-08-28 |
Genentech Inc |
Antitest-tisztítás kationcserés kromatográfiával
|
US20130195888A1
(en)
*
|
2007-11-30 |
2013-08-01 |
Abbvie |
Ultrafiltration and diafiltration formulation methods for protein processing
|
US8883146B2
(en)
*
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
CA2707483A1
(fr)
*
|
2007-11-30 |
2009-06-11 |
Wolfgang Fraunhofer |
Formulations de proteine et leurs procedes de fabrication
|
PL2271382T3
(pl)
|
2008-04-15 |
2013-08-30 |
Grifols Therapeutics Inc |
Dwuetapowa ultrafiltracja/diafiltracja
|
CA2733782A1
(fr)
*
|
2008-08-14 |
2010-02-18 |
Merck Sharp & Dohme Corp. |
Procedes de purification d'anticorps a l'aide d'une chromatographie d'affinite sur proteine a
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
NZ592644A
(en)
*
|
2008-11-28 |
2013-09-27 |
Abbott Lab |
Stable antibody compositions and methods for stabilizing same
|
FR2944448B1
(fr)
*
|
2008-12-23 |
2012-01-13 |
Adocia |
Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
|
SG174258A1
(en)
*
|
2009-03-06 |
2011-10-28 |
Genentech Inc |
Antibody formulation
|
AU2010249046A1
(en)
|
2009-05-13 |
2011-12-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
SG176256A1
(en)
|
2009-05-27 |
2012-01-30 |
Baxter Int |
A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
|
AU2010279569A1
(en)
*
|
2009-08-04 |
2012-03-01 |
Genentech, Inc. |
Concentrated polypeptide formulations with reduced viscosity
|
FR2958646B1
(fr)
|
2010-04-07 |
2012-05-18 |
Adocia |
Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
|
CA2788863C
(fr)
|
2010-02-04 |
2020-07-07 |
Reinhard Franz Bolli |
Preparation d'immunoglobuline
|
BR112012022258A2
(pt)
|
2010-03-01 |
2016-10-25 |
Bayer Healthcare Llc |
anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
TWI606840B
(zh)
|
2010-11-11 |
2017-12-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗-TNFα抗體之液體調配物
|
CA2831572C
(fr)
*
|
2011-05-02 |
2019-11-26 |
Immunomedics, Inc. |
Concentration d'ultrafiltration d'anticorps a allotype selectionne pour une administration de petit volume
|
US10300140B2
(en)
|
2011-07-28 |
2019-05-28 |
I2 Pharmaceuticals, Inc. |
Sur-binding proteins against ERBB3
|
CN104023743B
(zh)
|
2011-10-25 |
2017-05-03 |
普罗西纳治疗有限公司 |
抗体制剂和方法
|
EP3446707A1
(fr)
|
2011-12-22 |
2019-02-27 |
i2 Pharmaceuticals, Inc. |
Protéines se liant à un substitut
|
AU2013262083A1
(en)
|
2012-05-14 |
2014-11-06 |
Novo Nordisk A/S |
Stabilised protein solutions
|
WO2013190047A1
(fr)
*
|
2012-06-21 |
2013-12-27 |
Ucb Pharma S.A. |
Préparation pharmaceutique
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
HUE049282T2
(hu)
|
2012-09-07 |
2020-09-28 |
Coherus Biosciences Inc |
Adalimumab stabil vizes formulációi
|
JP2016504344A
(ja)
*
|
2012-12-28 |
2016-02-12 |
ノヴォ ノルディスク アー/エス |
高温デッドエンド抗体ろ過
|
CN105026417A
(zh)
*
|
2013-02-06 |
2015-11-04 |
新加坡科技研究局 |
用于降低蛋白质制剂中的聚集物含量的方法
|
EP3808338A1
(fr)
|
2013-09-11 |
2021-04-21 |
Eagle Biologics, Inc. |
Formulations de protéine liquides contenant des liquides ioniques
|
WO2015075201A1
(fr)
|
2013-11-21 |
2015-05-28 |
Genmab A/S |
Formulation lyophilisée de conjugués anticorps-médicaments
|
JP2014208669A
(ja)
*
|
2014-06-17 |
2014-11-06 |
株式会社スリー・ディー・マトリックス |
タンパク質の凝集抑制剤
|
AU2015325055B2
(en)
|
2014-10-01 |
2021-02-25 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
ES2964640T3
(es)
|
2015-08-13 |
2024-04-08 |
Amgen Inc |
Filtración en profundidad cargada de proteínas de unión al antígeno
|
RU2731418C2
(ru)
*
|
2015-09-28 |
2020-09-02 |
Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. |
Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
US20190030180A1
(en)
|
2016-01-13 |
2019-01-31 |
Genmab A/S |
Formulation for antibody and drug conjugate thereof
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
JP7114567B2
(ja)
*
|
2016-08-17 |
2022-08-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
生体分子を含む高濃縮液体製剤の調製のためのプロセス
|
BR112019007858A2
(pt)
|
2016-10-21 |
2019-07-02 |
Amgen Inc |
formulações farmacêuticas e métodos para produzir as mesmas
|
AU2017361539B2
(en)
*
|
2016-11-21 |
2023-06-29 |
Eiger Biopharmaceuticals, Inc. |
Buffered formulations of exendin (9-39)
|
TWI761453B
(zh)
*
|
2017-03-01 |
2022-04-21 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
CN110913906A
(zh)
|
2017-05-02 |
2020-03-24 |
默沙东公司 |
抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
|
EP3624846B1
(fr)
|
2017-05-16 |
2024-08-07 |
Bhami's Research Laboratory, Pvt. Ltd. |
Formulations de protéines à haute concentration ayant une viscosité réduite incluant une mixture d'acide nicotinique et tryoptophane
|
CN107490675B
(zh)
*
|
2017-08-10 |
2019-02-12 |
迈克生物股份有限公司 |
一种免疫比浊试剂盒及检测方法
|
CN107490676B
(zh)
*
|
2017-08-10 |
2019-02-12 |
迈克生物股份有限公司 |
一种补体c3检测试剂盒及检测方法
|
KR20210043607A
(ko)
*
|
2018-08-10 |
2021-04-21 |
암젠 인크 |
항체 제약 제형의 제조 방법
|
US11634485B2
(en)
|
2019-02-18 |
2023-04-25 |
Eli Lilly And Company |
Therapeutic antibody formulation
|
EP3808777A1
(fr)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Formulations d'anticorps liquides stables
|
JP7512762B2
(ja)
|
2020-08-20 |
2024-07-09 |
ニプロ株式会社 |
スガマデクス含有の液体製剤
|